← Leaderboards
Elliott P Vichinsky
University Of California San Francisco
$12,339,152
Attributed
$14,996,625
Total exposure
25
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,441,139 · 23
FDA$1,599,236 · 1
CDC$956,250 · 1
By mechanism
U01$7,699,713 · 3
R01$4,637,449 · 3
U54$1,720,565 · 2
R34$449,538 · 1
P60$232,867 · 1
M01$201,493 · 13
Top collaborators
- Marsha J Treadwell6 shared
- John Brooke Porter2 shared
- Charles S Abrams1 shared
- Ellen B Fung1 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- William C. Mentzer$232,867
- Lori A Styles$3,704,916
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectSickle Cell AnemiaHuman Therapy EvaluationThalassemiaBlood TransfusionHydroxyureaMagnetic Resonance ImagingMedical ComplicationChelation TherapyLongitudinal Human StudyPathologic ProcessStrokeBlood Disorder ChemotherapyAdultIron DisorderBiopsyCaringIronSickle CellAffectPreventClinical Trial Phase IMeasurement
Grant awards (80)
Zinc Supplementation in SCD: A Precursor to the Think Zinc for Bones Trial$449,538
R34 · FY2025 · HL
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease Care$559,570
U01 · FY2021 · HL · contact PI
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease Care$587,250
U01 · FY2020 · HL · contact PI
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease Care$820,293
U01 · FY2019 · HL · contact PI
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease Care$832,271
U01 · FY2018 · HL · contact PI
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease Care$615,512
U01 · FY2017 · HL · contact PI
SC-Links - Linking the Sickle Cell Community, Providers and Systems to Improve Sickle Cell Disease Care$655,656
U01 · FY2016 · HL · contact PI
Phase 2 Study of Deferiprone in the Treatment of NBIA$399,999
R01 · FY2015 · FD · contact PI
Phase 2 Study of Deferiprone in the Treatment of NBIA$399,999
R01 · FY2014 · FD · contact PI
Phase 2 Study of Deferiprone in the Treatment of NBIA$399,423
R01 · FY2013 · FD · contact PI
Phase 2 Study of Deferiprone in the Treatment of NBIA$399,815
R01 · FY2012 · FD · contact PI
Prevention of Complications in Thalassemia$200,000
U01 · FY2011 · DD · contact PI
Modulation of Iron Deposition in SCD and Other Hemoglobinopathies$312,469
R01 · FY2010 · DK · contact PI
Prevention of Complications in Thalassemia$150,000
U01 · FY2010 · DD · contact PI
Modulation of Iron Deposition in SCD and Other Hemoglobinopathies$332,541
R01 · FY2009 · DK · contact PI
Thalassemia Clinical Research Network$222,229
U01 · FY2009 · HL · contact PI
Prevention of Complications in Thalassemia$200,000
U01 · FY2009 · DD · contact PI
Ninth Cooley's Anemia Symposium$10,000
R13 · FY2009 · HL · contact PI
Thalassemia Clinical Research Network$215,789
U01 · FY2008 · HL · contact PI
Prevention of Complications in Thalassemia$200,000
U01 · FY2008 · DD · contact PI
CORE--CLINICAL RESEARCH 1$476,663
U54 · FY2007 · HL · contact PI
CORE--PATIENT SERVICE$283,019
U54 · FY2007 · HL · contact PI
Prevention of Complications in Thalassemia$206,250
U01 · FY2007 · DD · contact PI
Thalassemia Clinical Research Network$109,538
U01 · FY2007 · HL · contact PI
CORE--CLINICAL RESEARCH 1$305,929
U54 · FY2006 · HL · contact PI
Thalassemia Clinical Research Network$209,552
U01 · FY2006 · HL · contact PI
CORE--PATIENT SERVICE$181,407
U54 · FY2006 · HL · contact PI
CORE--CLINICAL RESEARCH 1$297,422
U54 · FY2005 · HL
Thalassemia Clinical Research Network$208,395
U01 · FY2005 · HL
CORE--PATIENT SERVICE$176,125
U54 · FY2005 · HL
Eighth Cooley's Anemia Symposium$45,000
R13 · FY2005 · HL
CONROL OF OXIDANT-STRESS INDUCED INJURY AND MITOCHRONDRIAL DYSFUNCTION BY TRE$19,816
M01 · FY2005 · RR
NATURAL HISTORY IRON$12,514
M01 · FY2005 · RR
NEUROPSYCH IN SCD$6,605
M01 · FY2005 · RR
COMPARISON OF COMBINATION THERAPY WITH MAGNESIUM PIDOATE AND HYDROXYUREA, VS$4,532
M01 · FY2005 · RR
CALIFORNIA THALASSEMIA CLINICAL RESEARCH CENTER$326,812
U01 · FY2004 · HL
SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD$240,000
R01 · FY2004 · DK
THAL OSTEO$49,984
M01 · FY2004 · RR
NATURAL HISTORY IRON$19,557
M01 · FY2004 · RR
Control of oxidant-stress induced injury and mitochrondrial dysfunction by tre...$4,186
M01 · FY2004 · RR
THAL$3,332
M01 · FY2004 · RR
Comparison of combination therapy with magnesium pidoate and hydroxyurea, vs....$1,904
M01 · FY2004 · RR
STOP II$1,190
M01 · FY2004 · RR
PARVOVIRUS$476
M01 · FY2004 · RR
CALIFORNIA THALASSEMIA CLINICAL RESEARCH CENTER$360,600
U01 · FY2003 · HL
SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD$240,000
R01 · FY2003 · DK
E/BETA THALASSEMIA--NATURAL HISTORY &RESPONSE TO CHEMO$410,701
R01 · FY2002 · HL
CALIFORNIA THALASSEMIA CLINICAL RESEARCH CENTER$350,096
U01 · FY2002 · HL
SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD$240,000
R01 · FY2002 · DK
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--PEDIATRIC HYDROXYUREA$0
M01 · FY2002 · RR
RANDOMIZED TRIAL FOR CORE DECOMPRESSION IN SICKLE CELL ANEMIA$0
P60 · FY2002 · HL
RANDOMIZED TRIAL FOR CORE DECOMPRESSION IN SICKLE CELL ANEMIA$0
P60 · FY2002 · HL
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--STROKE PREVENTION TRIAL$0
M01 · FY2002 · RR
COOPERATIVE STUDY OF SICKLE CELL DISEASE$0
M01 · FY2002 · RR
E/BETA THALASSEMIA--NATURAL HISTORY &RESPONSE TO CHEMO$399,155
R01 · FY2001 · HL
CALIFORNIA THALASSEMIA CLINICAL RESEARCH CENTER$339,900
U01 · FY2001 · HL
SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD$240,000
R01 · FY2001 · DK
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--STROKE PREVENTION TRIAL$0
M01 · FY2001 · RR
RANDOMIZED TRIAL FOR CORE DECOMPRESSION IN SICKLE CELL ANEMIA$0
P60 · FY2001 · HL
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--PEDIATRIC HYDROXYUREA$0
M01 · FY2001 · RR
COOPERATIVE STUDY OF SICKLE CELL DISEASE$0
M01 · FY2001 · RR
E/BETA THALASSEMIA--NATURAL HISTORY &RESPONSE TO CHEMO$387,947
R01 · FY2000 · HL
CALIFORNIA THALASSEMIA CLINICAL RESEARCH CENTER$330,000
U01 · FY2000 · HL
SECONDARY HEMOCHROMATOSIS IN BETA THALASSEMIA AND SCD$235,400
R01 · FY2000 · DK
RANDOMIZED TRIAL FOR CORE DECOMPRESSION IN SICKLE CELL ANEMIA$232,867
P60 · FY2000 · HL
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--PEDIATRIC HYDROXYUREA$25,799
M01 · FY2000 · RR
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--STROKE PREVENTION TRIAL$25,799
M01 · FY2000 · RR
COOPERATIVE STUDY OF SICKLE CELL DISEASE$25,799
M01 · FY2000 · RR
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--STROKE PREVENTION TRIAL$0
M01 · FY2000 · RR
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--STROKE PREVENTION TRIAL$0
M01 · FY2000 · RR
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--PEDIATRIC HYDROXYUREA$0
M01 · FY2000 · RR
PATHOPHYSIOLOGY AND TREATMENT IN SICKLE CELL DISEASE--PEDIATRIC HYDROXYUREA$0
M01 · FY2000 · RR
COOPERATIVE STUDY OF SICKLE CELL DISEASE$0
M01 · FY2000 · RR
COOPERATIVE STUDY OF SICKLE CELL DISEASE$0
M01 · FY2000 · RR
AVASCULAR NECROSIS OF THE HIP IN SICKLE CELL DISEASE$0
M01 · FY2000 · RR
AVASCULAR NECROSIS OF THE HIP IN SICKLE CELL DISEASE$0
M01 · FY2000 · RR
AVASCULAR NECROSIS OF THE HIP IN SICKLE CELL DISEASE$0
M01 · FY2000 · RR
MULTICENTER STUDY OF HYDROXYUREA IN SICKLE CELL DISEASE$0
M01 · FY2000 · RR
MULTICENTER STUDY OF HYDROXYUREA IN SICKLE CELL DISEASE$0
M01 · FY2000 · RR
MULTICENTER STUDY OF HYDROXYUREA IN SICKLE CELL DISEASE$0
M01 · FY2000 · RR